Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
This description comes directly from the study's public registry record.
Wei Guo · +86 13527323568 · gyguowei@hotmail.com
Always discuss trial participation with your own doctor first.
| Army Medical Center of the People's Liberation Army | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06354140